ACELRX PHARMACEUTICALS INC stock forecast: up to 2.11 USD ACRX stock price prognosis

STOCK

Forecast for Thu 30 Mar 2023 price 1.74

ACELRX PHARMACEUTICALS INC stock price forecast for further price development up to 6.12% (time horizon: 1 day) and price target of 2.11 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) ACELRX PHARMACEUTICALS INC share price prediction for 2023-03-30 with daily closed price projections

Key Facts

Symbol ACRX 

ISIN US00444T1007 

CUSIP 00444T100


Currency USD


Category Pharmaceutical Preparations

Forecast price change %


News sentiment (-0.50)


News <--> Close correlation for next day influence (-0.28)

Finance numbers

Revenue 5,541,000.0


Earnings per share -0.35


On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.

Summerized Form 10-K with GPT-2

xa0;   1     ACELRX PHARMACEUTICALS, INC. &# Financial Statements and Supplementary Data 71 Item 9. DSUVIA is not available in retail pharmacies or for outpatient use. The rights to market and sell Zalviso in the Territory revert back to us in May 2021. &# Each of the three Phase 3 trials successfully achieved its primary endpoint. Importantly, none of these device errors resulted in an over-dosing event. We also rely on trade secrets to protect DSUVIA, DZUVEO and Zalviso. Even if the patents do successfully issue, third parties may challenge the patents. &# This may render our products obsolete or non-competitive. This is an internationally recognized quality standard for medical devices. The requirements governing drug pricing vary widely from country to country. We recognize and support the growth and development of our employees. &# The EC granted marketing approval of DZUVEO in June 2018. As a result, the development timeline for Zalviso was further extended. &# There were no SAEs deemed related to study drug. &# Grünenthal terminated the collaboration, effective November 13, 2020. xa0; DSUVIA was approved in the United States with a REMS program. If Zalviso is approved in the United States, it will also require a REMS program. On August 31, 2020, PDL announced it sold its royalty interest for Zalviso to SWK. &# Such arrangements may not be available on favorable terms, if at all. &# Our contract manufacturers apply for quotas on our behalf. Our business may suffer if a finding of infringement is established. &# xa0; Recent Sales of Unregistered Securities   None. &# We will not detail and promote XERAVA™ (eravacycline) under this agreement. &# We sell our products primarily through wholesale distributors. &# We estimated this overhead rate by utilizing forecasted expenditures. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. Cost is determined using the first-in, first-out method for all inventories. The interest rate implicit in lease contracts is typically not readily determinable. xa0; Lease expense is recognized over the expected term on a straight-line basis. As a result, we no longer recognize deferred rent on the balance sheet. &# The total net proceeds from this offering were approximately $10.0 million. &# As of December 31, 2020, the accrued balance under the Loan Agreement was $21.0 million. xa0;     Item 16. xa0; We conducted our audits in accordance with the standards of the PCAOB. Zalviso is approved in Europe and is in late-stage development in the United States. Actual results could differ from those estimates. &# All intercompany accounts and transactions have been eliminated in consolidation. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. For further discussion, see Note 6 “Long-Term Debt”. &# This guidance provides a unified model to determine how revenue is recognized. The Company estimated this overhead rate by utilizing forecasted expenditures. For all other performance obligations, the Company uses a cost- plus margin approach. &# The Company eliminated 30 positions, primarily within the commercial organization. xa0; The headcount reduction was completed in the first quarter of 2020. 2021-01, “Reference Rate Reform (Topic 848): Scope&#x

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1427925/000143774921006074/0001437749-21-006074.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 60.76/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.
    • Stock price is under book price value.

Institutional ownership list is based on filling form information

Holding name Date Amount
Engineers Gate Manager LP 2021-03-31 241854
Edmonds Duncan Registered Investment Advisors, LLC 2021-06-30 41000
MILLENNIUM MANAGEMENT LLC 2021-03-31 1243741
Ahrens Investment Partners LLC 2021-06-30 68500
BRIDGEWAY CAPITAL MANAGEMENT, LLC 2021-03-31 666350

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Fidelity Concord Street Trust 2021-05-31 161025 Long
Fidelity Salem Street Trust 2021-04-30 407591 Long
Fidelity Concord Street Trust 2021-04-30 22928 Long
BlackRock Funds 2021-04-30 4827 Long
Fidelity Salem Street Trust 2021-04-30 5514 Long

Bollinger Bollinger Bands for ACELRX PHARMACEUTICALS INC can provide the information where the market is moving based on price information.


ACELRX PHARMACEUTICALS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.


On-Balance Volume information for ACELRX PHARMACEUTICALS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.


Accumulation / Distribution (A/D) indicator information for ACELRX PHARMACEUTICALS INC. The indicator identify divergences between price and volume flow.


Aroon Oscillator information for ACELRX PHARMACEUTICALS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.


Average Directional Index (ADX) information for ACELRX PHARMACEUTICALS INC. The index can be used to identify the strengh of a trend.


Moving Average Convergence Divergence (MACD) for ACELRX PHARMACEUTICALS INC. The indicator helps to predict trend direction and the momentum of the trend.


Stochastic Oscillator as momentum indicator for ACELRX PHARMACEUTICALS INC. The indicator is useful for identifying overbought and oversold levels.


Relative Strength Index (RSI) for ACELRX PHARMACEUTICALS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].


52W High 52W Low Market Cap

Similar shares


ACELRX PHARMACEUTICALS INC on Nasdaq

ACELRX PHARMACEUTICALS INC on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2023-02-03 2.11 2023-02-02 07:27
2023-02-06 2.14 2023-02-02 07:27
2023-02-07 2.09 2023-02-02 07:27
2023-02-08 2.11 2023-02-02 07:27
2023-02-09 2.06 2023-02-02 07:27
2023-02-10 2.11 2023-02-02 07:27
2023-02-13 2.07 2023-02-02 07:27
2023-02-14 2.10 2023-02-02 07:27
2023-02-15 2.04 2023-02-02 07:27
2023-02-16 2.03 2023-02-02 07:27
2023-02-17 1.96 2023-02-02 07:27
2023-02-20 1.99 2023-02-02 07:27
2023-02-21 1.94 2023-02-02 07:27
2023-02-22 1.96 2023-02-02 07:27
2023-02-23 1.91 2023-02-02 07:27
2023-02-24 1.94 2023-02-02 07:27
2023-02-27 1.88 2023-02-02 07:27
2023-02-28 1.91 2023-02-02 07:27
2023-03-01 1.86 2023-02-02 07:27
2023-03-02 1.89 2023-02-02 07:27
2023-03-03 1.85 2023-02-02 07:27
2023-03-06 1.88 2023-02-02 07:27
2023-03-07 1.84 2023-02-02 07:27
2023-03-08 1.86 2023-02-02 07:27
2023-03-09 1.82 2023-02-02 07:27
2023-03-10 1.84 2023-02-02 07:27
2023-03-13 1.81 2023-02-02 07:27
2023-03-14 1.83 2023-02-02 07:27
2023-03-15 1.79 2023-02-02 07:27
2023-03-16 1.81 2023-02-02 07:27
2023-03-17 1.78 2023-02-02 07:27
2023-03-20 1.79 2023-02-02 07:27
2023-03-21 1.76 2023-02-02 07:27
2023-03-22 1.78 2023-02-02 07:27
2023-03-23 1.75 2023-02-02 07:27
2023-03-24 1.76 2023-02-02 07:27
2023-03-27 1.74 2023-02-02 07:27
2023-03-28 1.75 2023-02-02 07:27
2023-03-29 1.73 2023-02-02 07:27
2023-03-30 1.74 2023-02-02 07:28